Updated:
Whitehead Institute for Biomedical Research
The Whitehead Institute was established in 1982 through a $135 million gift from industrialist Edwin C. Whitehead. David Baltimore served as its founding...
Whitehead Institute for Biomedical Research
The Whitehead Institute was established in 1982 through a $135 million gift from industrialist Edwin C. Whitehead. David Baltimore served as its founding director. The institute functions as both a research center and a grant-making entity focused on health and education. Its endowment portfolio contains common stocks, mutual funds, global equities, hedge funds, and resource funds. Confirmed holdings include long equity positions in Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, and Fate Therapeutics. Private investments cover CAMP4 Therapeutics, Dewpoint Therapeutics, Omega Therapeutics, Syros Pharmaceuticals, and Verastem Oncology. Activity centers on North America with primary operations in Cambridge, Massachusetts. The institute employs direct deal and philanthropic structures. It maintains membership in the Massachusetts Biotechnology Council and the Kendall Square Association. No dated operational events from the last 24 months appear in available records. The institute's architecture rests on its hybrid status as an independent research entity with a permanent MIT faculty tie. All Whitehead Members hold MIT appointments, creating a distinct governance and talent pipeline not replicated in standard endowments or foundations.
General information
Firm type
Endowment / Foundation
Year founded
1982
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Principals
Ruth Lehmann
Director and President
Edwin C. Whitehead
Founder
Sector focus
Frequently asked questions
Who runs investment decisions at Whitehead Institute for Biomedical Research?
Ruth Lehmann serves as Director and President. Investment oversight occurs through the institute's board and staff with support from external advisors including State Street Bank as custodian.
Does Whitehead Institute participate in fund commitments or only direct deals?
The institute makes direct investments in startups and holds public equity positions. It also maintains alternative investments including hedge funds and resource funds.
What investment stages does Whitehead Institute typically target?
Activity includes seed-stage commitments alongside public market holdings. Private positions focus on early biotechnology companies.
Where does the underlying wealth come from?
The institute was founded with a $135 million gift from Edwin C. Whitehead. Ongoing support flows from the Whitehead Foundation and investment returns.
How is Whitehead Institute related to MIT?
The institute shares a teaching and research affiliation with MIT. All Whitehead Members hold faculty appointments at MIT.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: